JP2017509649A5 - - Google Patents

Download PDF

Info

Publication number
JP2017509649A5
JP2017509649A5 JP2016558023A JP2016558023A JP2017509649A5 JP 2017509649 A5 JP2017509649 A5 JP 2017509649A5 JP 2016558023 A JP2016558023 A JP 2016558023A JP 2016558023 A JP2016558023 A JP 2016558023A JP 2017509649 A5 JP2017509649 A5 JP 2017509649A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
seq
dose
body weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2016558023A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017509649A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/021551 external-priority patent/WO2015143209A1/en
Publication of JP2017509649A publication Critical patent/JP2017509649A/ja
Publication of JP2017509649A5 publication Critical patent/JP2017509649A5/ja
Withdrawn legal-status Critical Current

Links

JP2016558023A 2014-03-19 2015-03-19 Ｃｄ４０ｌに対するドメイン抗体を用いる移植拒絶を治療する方法 Withdrawn JP2017509649A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461955588P 2014-03-19 2014-03-19
US61/955,588 2014-03-19
PCT/US2015/021551 WO2015143209A1 (en) 2014-03-19 2015-03-19 Methods of treating transplant rejection using a domain antibody directed against cd40l

Publications (2)

Publication Number Publication Date
JP2017509649A JP2017509649A (ja) 2017-04-06
JP2017509649A5 true JP2017509649A5 (https=) 2018-04-05

Family

ID=53055087

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016558023A Withdrawn JP2017509649A (ja) 2014-03-19 2015-03-19 Ｃｄ４０ｌに対するドメイン抗体を用いる移植拒絶を治療する方法

Country Status (13)

Country Link
US (2) US20170051059A1 (https=)
EP (1) EP3119809A1 (https=)
JP (1) JP2017509649A (https=)
KR (1) KR20160124912A (https=)
CN (1) CN106132429A (https=)
AU (1) AU2015231180B2 (https=)
BR (1) BR112016018813A2 (https=)
CA (1) CA2943177A1 (https=)
EA (1) EA201691634A1 (https=)
IL (1) IL247048A0 (https=)
MX (1) MX2016011102A (https=)
SG (1) SG11201606521VA (https=)
WO (1) WO2015143209A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20110385A1 (es) * 2008-07-18 2011-06-22 Bristol Myers Squibb Co Anticuerpo de dominio (dab) que se une a cd28 y no reacciona en forma cruzada con ctla4
SMT202000091T1 (it) 2011-10-13 2020-05-08 Bristol Myers Squibb Co Polipeptidi anticorpali che antagonizzano cd40l
MX2017003691A (es) * 2014-09-30 2017-06-26 Bristol Myers Squibb Co Metodos para tratar lupus eritematoso sistemico usando un anticuerpo de dominio dirigido contra cd28.
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
KR20180080337A (ko) * 2015-11-27 2018-07-11 아블린쓰 엔.브이. Ｃｄ40ｌ을 억제하는 폴리펩티드
WO2017160975A1 (en) 2016-03-16 2017-09-21 Bristol-Myers Squibb Company Methods of diagnosing and treating lupus
KR102840867B1 (ko) * 2017-05-24 2025-07-30 에이엘에스 테라피 디벨럽먼트 인스티튜트 치료용 항-cd40 리간드 항체
RS66218B1 (sr) * 2019-07-01 2024-12-31 Tonix Pharma Ltd Anti-cd154 antitela i njihove upotrebe
WO2024211211A1 (en) 2023-04-03 2024-10-10 Regeneron Pharmaceuticals, Inc. Methods of improving transplant survival using il-2 receptor gamma chain antibodies

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
ATE447412T1 (de) * 2003-11-04 2009-11-15 Novartis Vaccines & Diagnostic Antagonist-anti-cd40-monoklonale antikörper und anwendungsverfahren
US8277810B2 (en) * 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
JP2008535841A (ja) 2005-04-06 2008-09-04 ブリストル−マイヤーズ スクイブ カンパニー 可溶性ｃｔｌａ４変異分子によるグラフト移植に関連する免疫不全の治療方法
US8476239B2 (en) 2005-12-20 2013-07-02 Bristol-Myers Squibb Company Stable protein formulations
PE20110385A1 (es) * 2008-07-18 2011-06-22 Bristol Myers Squibb Co Anticuerpo de dominio (dab) que se une a cd28 y no reacciona en forma cruzada con ctla4
SMT202000091T1 (it) 2011-10-13 2020-05-08 Bristol Myers Squibb Co Polipeptidi anticorpali che antagonizzano cd40l

Similar Documents

Publication Publication Date Title
JP2017509649A5 (https=)
US20240174745A1 (en) Antibody Constructs for CLDN18.2 and CD3
CN111448211B (zh) 抗cd39抗体、包含抗cd39抗体的组合物和使用抗cd39抗体的方法
JP7682150B2 (ja) プロテアーゼ活性化治療剤を含む組成物および方法
JP7665600B2 (ja) 抗腫瘍溶解性ウイルス抗原抗体およびその使用方法
JP2018502060A5 (https=)
JP6763529B2 (ja) 抗クローディン−２モノクローナル抗体
SI2593128T1 (en) Humanized antibodies targeting the EC1 Kaderina-11 domain and associated compositions and procedures
KR20220019806A (ko) 가용성 보체 수용체 1형 변이체 접합체 및 이의 용도
EP4683948A1 (en) Cd19/cd38 multispecific antibodies
KR20220159989A (ko) C19 c38 이중특이적 항체
JP2017524675A5 (https=)
CA3238406A1 (en) Bispecific antibody and use thereof
CN103417965A (zh) 一种含有抗vegf抗体的药物组合物
CA3185332A1 (en) Recombinant rhabdovirus encoding for a cd80 extracellular domain fc-fusion protein
AU2020316002B2 (en) Compositions and methods comprising protease-activated therapeutic agents
CA3107192C (en) Antibody constructs for cldn18.2 and cd3
WO2025174812A1 (en) Chimeric antigen receptor and/or synnotch receptor systems and cells and methods of their use
CN120437287A (zh) 一种包含特异性结合gucy2c和cd3的双特异性抗体的药物组合物
ES2860973T3 (es) Diacuerpos monovalentes biespecíficos que pueden unirse a CD123 y CD3 y usos de estos
WO2023036815A1 (en) Targeted regulation of platelet and megakaryocyte activation by heteroreceptor co-clustering
HK40078027B (zh) 针对ror1的抗体及其用途